Argos Therapeutics, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on November 30, 2018. The debtor seeks the Court’s approval for the sale of substantially all its assets to Cellscript, LLC and Immune and Cell Therapies, LLC, the stalking horse bidder, for a purchase price of $3.82 million, pursuant to the asset purchase agreement, dated November 30, 2018. The purchase price include $1.68 million in cash, assumed liabilities of $1.44 million and release of stalking horse bidder's $2 million unsecured claims, estimated at $0.70 million. To qualify as a qualified bidder, interested parties should submit their bids by January 16, 2019, along with good-faith deposit in the amount of $0.17 million. The initial minimum overbid should be at least $0.13 million more than the initial purchase price. The debtor has scheduled an auction on January 22, 2019. At the auction, the subsequent bids would be in increments of $0.1 million. The stalking horse bidder would be entitled to a break-up fee of $0.08 million and expense reimbursement of $0.08 million in case of termination of the asset purchase agreement. Joseph W. Boucher of Neider & Boucher, S.C. and Margaret R. Westbrook and Aaron Rothman of K&L Gates, LLP acted as legal counsels for the buyer.